SLC20A2: A Potential Drug Target and Biomarker (G6575)

Target Name: SLC20A2

NCBI ID: G6575

SLC20A2

SLC20A2: A Potential Drug Target and Biomarker

Solute carrier family 20 (SLC20) member 2 (SLC20A2) is a protein that is expressed in various tissues and organs, including the brain, heart, and kidneys. It plays a crucial role in the transport of solutes, including ions and nutrients, across cell membranes. SLC20A2 is also known as NHE3 (Na+-hypotensin-3), which is a subunit of the Na+-hypotensin system.

The Na+-hypotensin system is a complex protein that is responsible for maintaining the homeostasis of sodium levels in the body. It is composed of two subunits, NHE1 (Na+-hypotensin 1) and NHE2 (Na+-hypotensin 2), which are encoded by the SLC20A1 and SLC20A2 genes, respectively. SLC20A2 is a 21-kDa protein that consists of 125 amino acid residues. It has a unique structure that is composed of a N-terminal region, a transmembrane region, and an C-terminal region.

SLC20A2 is expressed in various tissues and organs, including the brain, heart, and kidneys. It is highly expressed in the brain, where it is found in the basal ganglia, the dopamine neurons, and the glial cells. It is also expressed in the heart, where it is found in the cardiac muscle cells and in the pericardial sac. SLC20A2 is expressed in the kidneys, where it is found in the collecting tubules and in the interstitial cells.

SLC20A2 plays a crucial role in the transport of solutes across cell membranes. It is a subunit of the Na+-hypotensin system, which is responsible for maintaining the homeostasis of sodium levels in the body. It is composed of two subunits, NHE1 (Na+-hypotensin 1) and NHE2 (Na+-hypotensin 2), which are encoded by the SLC20A1 and SLC20A2 genes, respectively. SLC20A2 is a 21-kDa protein that consists of 125 amino acid residues. It has a unique structure that is composed of a N-terminal region, a transmembrane region, and an C-terminal region.

SLC20A2 has been identified as a potential drug target and biomarker. Several studies have shown that SLC20A2 is involved in various physiological processes, including neuronal signaling, ion transport, and inflammation. SLC20A2 has been shown to play a role in the regulation of neuronal signaling, including the transmission of action potentials in the brain. It has also been shown to play a role in the regulation of ion transport, including the transport of ions across the blood-brain barrier. SLC20A2 has also been shown to be involved in the regulation of inflammation, including the regulation of inflammation-related signaling pathways.

SLC20A2 has been shown to have potential therapeutic applications. Several studies have shown that inhibiting SLC20A2 can protect against neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. SLC20A2 has also been shown to be involved in the regulation of pain perception, including the regulation of pain modulation.

In conclusion, SLC20A2 is a protein that is expressed in various tissues and organs, including the brain, heart, and kidneys. It plays a crucial role in the transport of solutes, including ions and nutrients, across cell membranes. SLC20A2 is also known as NHE3 (

Protein Name: Solute Carrier Family 20 Member 2

Functions: Sodium-phosphate symporter which seems to play a fundamental housekeeping role in phosphate transport by absorbing phosphate from interstitial fluid for normal cellular functions such as cellular metabolism, signal transduction, and nucleic acid and lipid synthesis. In vitro, sodium-dependent phosphate uptake is not significantly affected by acidic and alkaline conditions, however sodium-independent phosphate uptake occurs at acidic conditions. May play a role in extracellular matrix, cartilage and vascular calcification. Functions as a retroviral receptor and confers human cells susceptibility to infection to amphotropic murine leukemia virus (A-MuLV), 10A1 murine leukemia virus (10A1 MLV) and some feline leukemia virus subgroup B (FeLV-B) variants

The "SLC20A2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC20A2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets